#United States #New York #Rosen Law Firm #securities claims #Immutep Ltd

Rosen Law Firm Investigates Immutep Ltd. Securities Class Action

Rosen Law Firm, a prominent global law firm dedicated to investor rights, is launching an investigation into the actions of Immutep Ltd. (NASDAQ: IMMP). This inquiry pertains to potential securities claims that may arise due to allegations of the company providing misleading business information to its investors.

Understanding the Situation

On March 13, 2026, Immutep released a statement regarding an important trial related to its drug, eftilagimod alfa, aimed at treating patients with non-small cell lung cancer. This announcement indicated that the Independent Data Monitoring Committee (IDMC) recommended halting the trial following their analysis of the available efficacy and safety data. This unexpected decision has raised concerns amongst investors, as it may suggest that Immutep may have not been transparent about the trial's outcomes.

Consequently, this news resulted in a staggering decline in the price of Immutep's American Depositary Receipt (ADR), which plummeted by 82.6%, closing at $0.48 per ADR. For investors who acquired shares during a time of perceived stability, this dramatic downturn is nothing short of alarming.

The Role of Rosen Law Firm

Shareholders of Immutep Ltd. who experienced losses could potentially recover their investments without any upfront costs, thanks to a contingency fee arrangement that the Rosen Law Firm is offering. This means that investors can join the anticipated class action lawsuit without bearing any out-of-pocket expenses. The firm encourages those affected to take action swiftly to ensure their inclusion.

Investors can register their interest in joining the class action by visiting the Rosen Law Firm’s dedicated web page or by contacting Phillip Kim, Esq., who is leading the case, through provided phone numbers and emails.

Rosen Law Firm's expertise in handling securities class actions is well-established. The firm has an impressive track record of securing favorable outcomes for investors, having recovered hundreds of millions of dollars over the years. In fact, since 2013, they have consistently ranked in the top echelon of firms concerning successful securities class action settlements.

Why Choose Rosen?

The Rosen Law Firm urges investors to opt for legal counsel that possesses a strong reputation and history in litigation. Many firms offering such notices may lack the essential experience or resources required to navigate the complexities tied to securities litigation effectively. With a history of significant settlements, including one of the largest against a Chinese company, Rosen Law Firm is equipped to represent investors adequately.

Moreover, the firm has been recognized by industry publications such as Law360 and has received accolades for its work in the field. Founding partner Laurence Rosen was notably acclaimed by Law360 as a Titan of the Plaintiffs' Bar in 2020.

Looking Ahead

As the investigation progresses, Rosen Law Firm will keep potential plaintiffs updated via various social media platforms, including LinkedIn, Twitter, and Facebook. Those who believe they might have a claim should not delay in seeking legal advice, to ensure they do not miss the opportunity to seek damages for their losses.

In conclusion, if you are an investor in Immutep Ltd. and have been impacted by these recent developments, consider reaching out to the Rosen Law Firm to understand your legal options. This could be a critical step towards reclaiming your investments.

Contact the Rosen Law Firm
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Email: [email protected]
Website: rosenlegal.com